IRSF Physician Panel: Answering Your Questions About Trofinetide  
 
    IRSF Parent Panel: My Trofinetide Clinical Trial Experience  
 
    Proactive interview, 20 March 2023  
 
    Ausbiz interview, 14 March 2023  
 
    Finance News Network interview, 13 March 2023  
 
    Neuren on Marcus Today Podcast, 7 Nov 2022  
 
    Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference  
 
    AusBiz interview 22 June 2022  
 
    Australian Financial Review article 4 Apr 2022  
 
    AusBiz interview 8 December 2021  
 
    Peak TV interview 2 July 2021  
 
    Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591  
 
    Neuren Pharmaceuticals 'in unique position' as it receives key approval for NNZ-2591 trial  
 
    Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome  
 
    Neuren Pharmaceuticals gets green light for a patent in the U.S.  
 
    Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials  
 
    Neuren Pharmaceuticals drug shows promise in treating Rett syndrome  
 
    Neuren Pharmaceuticals granted ASX trading halt pending trial update  
 
    Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome  
 
    Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome  
 
    Neuren Pharmaceuticals Ltd to reveal clinical results  
 
    Neuren Pharmaceuticals seeks “orphan drug” status for Rett Syndrome treatment  
 
    Neuren Pharmaceuticals makes Rett Syndrome trial breakthrough  
 
    Neuren Pharmaceuticals granted halt pending trial results  
 
    Neuren Pharmaceuticals to enrol subjects for concussion trial  
 
    Neuren Pharmaceuticals gains increased funding for brain injury drug trials  
 
    Neuren Pharmaceuticals completes enrolment for Rett Syndrome clinical trial  
 
    Neuren Pharmaceuticals progresses Phase 2 trials for brain treatment drug  
 
    Neuren Pharmaceuticals' shares trade heavy volume  
 
    Neuren Pharmaceuticals raises $21.5M to commercialise brain treatment drugs  
 
    Neuren Pharmaceuticals launches capital raising  
 
    Neuren Pharmaceuticals gets nod from FDA to trial new drug for Autism  
 
    Neuren Pharmaceuticals cranks up the volume with 11 million shares traded  
 
    Neuren Pharmaceuticals in pre-open to address market chatter  
 
    Neuren Pharmaceuticals receives notice of allowance by USPTO for neuropathy patents  
 
    Neuren Pharmaceuticals given US approval for clinical trial of Rett Syndrome drug  
 
    Neuren Pharmaceuticals’ 53% share price jump prompts ASX query  
 
    Neuren Pharmaceuticals gains grant for Phase 2 trials of Neuren Rett Syndrome treatment  
 
    Neuren Pharmaceuticals responds to ASX after 81% spike prompts price query  
 
    Neuren Pharmaceuticals to begin testing antibodies used for cancer treatment  
 
    Neuren Pharmaceuticals progresses post-brain injury drug in clinical trials